World Coronavirus Dispatch: Beijing pips global hubs with 80% jab rate

CureVac's shares plunge as vaccine disappoints, Japan set to lift some curbs ahead of Tokyo Olympics, and other pandemic-related news across the globe

CureVac loses billions of dollars in market value after vaccine fails in trial

German firm CureVac's shares plunged over 50 per cent, wiping out $9 billion in market value as its vaccine showed only 47 per cent efficacy in a crucial trial, even though the findings are preliminary. The firm's shot fell way short of expectations when compared with the bar set by other mRNA vaccines. More details will emerge in the final readout of the study, which will include more than 200 cases and could come within two or three weeks, CureVac said. The shot could be a boost in